Translating advances in schizophrenia treatment: A glass ceiling

Medical Journal of Australia

Volumn 178, Issue 9, 2003, Pages 425-426

  McGorry, Patrick D ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

AUSTRALIA; CLINICAL PRACTICE; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; FAMILY; HEALTH CARE COST; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LOW DRUG DOSE; MENTAL HEALTH CARE; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PSYCHOTHERAPY; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL PSYCHOLOGY; STRESS; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 0038061510     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05282.x     Document Type: Editorial

References (15)

1. Burdekin B, Guilfoyle M, Hall D. Human Rights and Mental Illness. Report of the National Inquiry into the Human Rights of People with Mental Illness. Canberra: AGPS, 1993.
2. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 2002; 32: 763-782.
3. Edwards J, McGorry PD, editors. Implementing Early Intervention in Psychosis: A Guide to Establishing Early Psychosis Services. London: Dunitz, 2002.
4. Jablensky A, McGrath J, Herrman H, et al. People Living with Psychotic Illness: An Australian Study 1997-98. Canberra: Commonwealth Department of Health and Aged Care, 1999.
5. McGorry PD, Yung AR. Early intervention in psychosis: An overdue reform. An introduction to the Early Psychosis Symposium. Aust N Z J Psychiatry Supplement 2003. In press.
6. Auditor General Victoria. Mental Health Services for People in Crisis. Melbourne: Government Printer for the State of Victoria, 2002.
7. McGorry PD, Killackey E, Lambert T, Lambert M. Summary Australian and New Zealand College of Psychiatrists Guidelines for the treatment of schizophrenia 2003. Australas Psychiatry 2003. In press.
8. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: National Institute for Clinical Health Excellence, 2002.
9. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
10. Czernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22.
11. Meltzer HY, Alphs L, Green AI, et al, for the InterSePT Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePt). Arch Gen Psychiatry 2003; 60: 82-91.
12. Morgan V, Castle D, Jablensky A. The Use of Psychopharmacological and Other Treatments by Persons with Psychosis. Canberra: Commonwealth Department of Health and Ageing, 2002.
13. Andrews G, Sanderson K, Corry J, et al. The cost effectiveness of current and optimal treatment for schizophrenia: Evidence based medicine is affordable. Br J Psychiatry 2003. In press.
14. SANE Australia. Schizophrenia: Costs. An analysis of the burden of schizophrenia and related suicide in Australia. Access Economics Report for SANE Australia, 2002. Available at: http://www.sane.org/szcosts.pdf (accessed Apr 2003).
15. Sartorius N. Stigma: What can psychiatrists do about it? Lancet 1998; 352: 1058-1059.